BC Advantage Funds

Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment, traumatic brain injury, stroke, multiple sclerosis and neuropathy. Allon’s drug discovery platform has resulted in the development of a unique class of peptide compounds that has demonstrated broad efficacy in numerous pre-clinical and clinical models of neurodegenerative diseases.

Aquinox Pharmaceuticals Inc. is a pharmaceutical company committed to the discovery, development, and commercialization of novel and targeted small molecule therapeutics for the treatment of cancer and inflammatory disease. Aquinox's scientific founders discovered a unique biochemical enzyme called SH2-containing inositol 5'-phosphatase (known as SHIP), which can be harnessed in the treatment disorders such as multiple myeloma, leukemia, lymphoma, inflammation, allergy and autoimmune diseases.

Contigo Systems Inc. is a leading provider of location-based services using wireless and GPS technology for asset-tracking, fleet management and personal safety applications. Having commercialized a full, web-based solution for employing GPS and mobile solutions to track commercial vehicle fleets, assets and individuals, Contigo’s solutions are distributed under the same name across the U.S. and Canada through a broad network of security companies and GPS resellers.

GaleForce Solutions Inc. is a leading provider of customer relationship management (CRM) software for the financial services industry based on the Microsoft Dynamics platform. GaleForce CRM is an enterprise-class application uniquely suited to the daily workflow of client-facing producers in the financial services industry, including commercial and retail banks, wealth management and capital markets firms.

Inimex Pharmaceuticals Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body’s innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease.

IP Applications (TSX-V:IPX) provides technologies and services that enable Software Companies and IP service providers to manage product plans, pricing, subscribers and payment over the internet.

Medical Ventures Corp. (TSX-V:MEV) develops, manufactures and markets medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity.

Mobidia, Inc. provides wireless operators with the ability to better control, manage, and monetize IP data traffic and offer their mobile subscribers innovative and compelling new services.

MSI Methylation Sciences, Inc. Methylation Sciences is a life science company, focused on reformulating and developing a widely used nutraceutical, with proven safety and efficacy in humans, as a new pharmaceutical for the treatment of depression. MSI is led by an experienced management team including Barry Guld and Nancy Harrison.

NxtGen Emission Controls Inc. is an emerging supplier and technology innovator in hydrocarbon fuel processing and is leveraging this technology to support clean diesel, advanced gasoline and alternative fuel engine applications.

OncoGeneX Technologies Inc. is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies, designed to inhibit the production of specific proteins associated with treatment resistance, and which are over-produced in response to a variety of cancer treatments.

Pherotech International Inc. is a revenue-producing company offering a unique combination of natural pheromone based products for non-toxic pest management in home and garden, forestry, landscape, agriculture, and commercial applications.

Protox Therapeutics Inc. (TSX:PRX) is at the forefront of developing novel treatments in the emerging field of targeted toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), in the development of therapeutic products for its clinical programs.

Sirius Genomics Inc. is a pharmacogenomics and diagnostics company developing DNA-based diagnostic (Dx) and pharmacogenetic (PGx) tests for critical care. Sirius’ product focus is currently concentrated on the development of Dx and PGx tests for sepsis, a systemic blood infection.

Urodynamix Technologies Ltd.

(TSX-V:URO) is a medical device company that develops and commercializes non-invasive medical devices based on proprietary applications of near-infrared spectroscopy (NIRS) for the diagnosis of urological diseases and conditions.

Vigil Health Solutions Inc. (TSX-V:VGL) offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding aged care market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration.

Voice Mobility International Inc. (TSX:VMY) is a developer and provider of carrier and enterprise enhanced messaging solutions aimed at replacing aging voice mail systems currently deployed and at introducing new enhanced messaging and unified communications capabilities, at a lower total cost of ownership than competitors.

Zeugma Systems Inc. is developing and selling next generation network element designed to optimally deliver voice, video, and data services over a converged broadband network. Zeugma’s product, the Zeugma Service Node (ZSN), delivers the intelligence necessary to optimize quality of service and experience of internet subscribers.